2011
DOI: 10.1212/wnl.0b013e31821e7c8a
|View full text |Cite
|
Sign up to set email alerts
|

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

28
279
6
7

Year Published

2012
2012
2022
2022

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 285 publications
(320 citation statements)
references
References 17 publications
28
279
6
7
Order By: Relevance
“…As in other reports [8,16,17], younger patients and those with more pretreatment Gd? activity were more likely to have return of Gd?…”
Section: Timing Of Gd? Lesion Appearancesupporting
confidence: 79%
See 2 more Smart Citations
“…As in other reports [8,16,17], younger patients and those with more pretreatment Gd? activity were more likely to have return of Gd?…”
Section: Timing Of Gd? Lesion Appearancesupporting
confidence: 79%
“…Discontinuation of natalizumab is associated with return of MS disease activity [7][8][9][10][11][12][13][14][15][16][17][18][19][20]. Some reports suggest disease activity after natalizumab cessation exceeds baseline levels [11,13,16,18,19,[21][22][23], while other studies do not [12,14,17,24].…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Such a rebound effect has previously been described after interruption of NTZ treatment. An analysis of >1800 patients who stopped NTZ therapy showed that relapse of disease activity was particularly evident in patients who had had highly active disease before NTZ therapy 42. Similarly, there are some case reports of exacerbation after discontinuation of FTY 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56.…”
Section: Rebound After Withdrawal Of Fingolimodmentioning
confidence: 99%
“…2,19,20 After discontinuation of natalizumab therapy, disease activity returned, with 21% of patients experiencing a relapse within 8 months of stopping treatment, 19 and disability, which had been stable for 2 years with natalizumab use, increased. 2 However, these data provided no information on whether the return of disease activity and disability progression could be mitigated by switching to alternative therapies.…”
Section: Sf-12 Pcs Changementioning
confidence: 99%